{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:45:08Z","timestamp":1793810708426,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.maturitas.2025.108620","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T02:40:58Z","timestamp":1748313658000},"page":"108620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intravaginal prasterone for urinary urgency in postmenopausal women without urodynamic detrusor overactivity"],"prefix":"10.1016","volume":"199","author":[{"given":"Stefano","family":"Pautasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Mancarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Novara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Carignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Chiad\u00f2 Piat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Elisabetta","family":"Bounous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Giuseppe","family":"Sgro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.maturitas.2025.108620_bb0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"Schaer GN; international Urogynecological association; international continence society. An international Urogynecological association (IUGA)\/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol.Urodyn."},{"key":"10.1016\/j.maturitas.2025.108620_bb0010","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.maturitas.2025.108620_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-5347(05)00067-4","article-title":"Is the bladder a reliable witness for predicting detrusor overactivity?","volume":"175","author":"Hashim","year":"2006","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.maturitas.2025.108620_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/luts.12153","article-title":"Comparative efficacy and tolerability of Antimuscarinic agents and the selective \u03b23-adrenoceptor agonist, Mirabegron, for the treatment of overactive bladder: which is more preferable as an initial treatment?","volume":"10","author":"Kobayashi","year":"2018","journal-title":"Low Urin Tract Symptoms."},{"issue":"5","key":"10.1016\/j.maturitas.2025.108620_bb0025","article-title":"Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults","volume":"5","author":"Stoniute","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.maturitas.2025.108620_bb0030","first-page":"349","article-title":"Maturitas","volume":"79","author":"Portman","year":"2014"},{"issue":"10","key":"10.1016\/j.maturitas.2025.108620_bb0035","article-title":"Oestrogen therapy for urinary incontinence in post-menopausal women","volume":"10","author":"Cody","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.maturitas.2025.108620_bb0040","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/GME.0000000000002007","article-title":"Prasterone in the treatment of mild to moderate urge incontinence: an observational study","volume":"29","author":"Coll\u00e0 Ruvolo","year":"2022","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.maturitas.2025.108620_bb0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2053369116633017","article-title":"The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women","volume":"22","author":"Chughtai","year":"2016","journal-title":"Post Reprod Health."},{"key":"10.1016\/j.maturitas.2025.108620_bb0050","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/GME.0000000000000808","article-title":"Science of intracrinology in postmenopausal women","volume":"24","author":"Labrie","year":"2017","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.maturitas.2025.108620_bb0055","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/gme.0b013e31819e8930","article-title":"Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.maturitas.2025.108620_bb0060","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/GME.0000000000001238","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"25","author":"Labrie","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2025.108620_bb0065","series-title":"Urodynamic and videourodynamic evaluation of voiding dysfunction","year":"2007"},{"key":"10.1016\/j.maturitas.2025.108620_bb0070","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/nau.23124","article-title":"International continence society good urodynamic practices and terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study","volume":"36","author":"Rosier","year":"2017","journal-title":"Neurourol.Urodyn."},{"issue":"1","key":"10.1016\/j.maturitas.2025.108620_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(83)90126-4","article-title":"The validation of visual analogue scales as ratio scale measures for chronic and experimental pain","volume":"17","author":"Price","year":"1983","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.maturitas.2025.108620_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/nau.22559","article-title":"An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF","volume":"34","author":"Coyne","year":"2015","journal-title":"Neurourol.Urodyn."},{"issue":"1","key":"10.1016\/j.maturitas.2025.108620_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12955-021-01721-z","article-title":"Iden ca on of the urogenital distress Inventory-6 and the incontinence impact ques onnaire-7 cuto scores in urinary incon nent women","volume":"19","author":"Skorupska","year":"2021","journal-title":"Health Qual. Life Outcomes"},{"issue":"5","key":"10.1016\/j.maturitas.2025.108620_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2009.02.007","article-title":"Pelvic floor disorders network. The minimum important differences for the urinary scales of the pelvic floor distress inventory and pelvic floor impact questionnaire","volume":"200","author":"Barber","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9596","key":"10.1016\/j.maturitas.2025.108620_bb0095","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE)statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.maturitas.2025.108620_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00192-011-1585-y","article-title":"Normal urodynamic parameters in women: part II--invasive urodynamics","volume":"23","author":"Mahfouz","year":"2012","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.maturitas.2025.108620_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejogrb.2021.06.009","article-title":"Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: a pilot study","volume":"263","author":"Matarazzo","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"3","key":"10.1016\/j.maturitas.2025.108620_bb0110","first-page":"779398","article-title":"Genitourinary syndrome of menopause: epidemiology, physiopathology, clinical Manifesta on and Diagnos c. front","volume":"15","author":"Sarmento","year":"2021","journal-title":"Reprod. Health"},{"key":"10.1016\/j.maturitas.2025.108620_bb0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2020.05.001","article-title":"Potential effectiveness of Ospemifene on detrusor Overactivity in patients with vaginal atrophy","volume":"138","author":"Novara","year":"2020","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.maturitas.2025.108620_bb0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00404-012-2596-8","article-title":"What is the success of drug treatment in urge urinary incontinence? What should be measured?","volume":"287","author":"Dede","year":"2013","journal-title":"Arch. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.maturitas.2025.108620_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20583","article-title":"Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome","volume":"28","author":"Tseng","year":"2009","journal-title":"Neurourol.Urodyn."},{"issue":"4","key":"10.1016\/j.maturitas.2025.108620_bb0130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SPV.0000000000000256","article-title":"Combined Tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment","volume":"22","author":"Ellington","year":"2016","journal-title":"Female Pelvic Med. Reconstr. Surg."},{"issue":"9","key":"10.1016\/j.maturitas.2025.108620_bb0135","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/gme.0b013e3182104977","article-title":"Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder","volume":"18","author":"Nelken","year":"2011","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.maturitas.2025.108620_bb0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40266-024-01116-x","article-title":"Associations between midlife anticholinergic medication use and subsequent cognitive decline: a british birth cohort study","volume":"41","author":"Rawle","year":"2024","journal-title":"Drugs Aging"},{"issue":"8","key":"10.1016\/j.maturitas.2025.108620_bb0145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40266-019-00693-6","article-title":"Prasterone: a review in vulvovaginal atrophy","volume":"36","author":"Heo","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.maturitas.2025.108620_bb0150","first-page":"8","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.maturitas.2025.108620_bb0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/medicina58040525","article-title":"Quality of life, psychological wellbeing, and sexuality in women with urinary incontinence-where are we now: a narrative review","volume":"58","author":"Frigerio","year":"2022","journal-title":"Medicina"},{"issue":"4","key":"10.1016\/j.maturitas.2025.108620_bb0160","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/nau.24331","article-title":"Estriol serum levels in new and chronic users of vaginal estriol cream: a prospective observational study","volume":"39","author":"Te West","year":"2020","journal-title":"Neurourol.Urodyn."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512225004281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512225004281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:43:51Z","timestamp":1754318631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512225004281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"alternative-id":["S0378512225004281"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2025.108620","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravaginal prasterone for urinary urgency in postmenopausal women without urodynamic detrusor overactivity","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2025.108620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108620"}}